CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Roberto M. Lemoli, Atto Bilio et al.|Blood Cancer Journal|2020Cited by 58
Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Robin Foà, Sabina Chiaretti et al.|Blood|2025Cited by 37
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 TrialSabina Chiaretti, Renato Bassan, Irene Della Starza et al.|Blood|2023Cited by 28
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus <scp>ALL</scp> studyMichelina Dargenio, Robin Foà, Massimiliano Bonifacio et al.|British Journal of Haematology|2022Cited by 19
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 TrialMarco Beldinanzi, Sabina Chiaretti, Vittorio Bellomarino et al.|Blood|2024Cited by 0